Novartis obtains licences to develop and commercialise two Ablynx Nanobodies

13-Jul-2010 - Belgium

Ablynx announced that Novartis has obtained licenses to further develop and commercialise Nanobodies against two complex targets. This has triggered a total of €1 million in upfront fees and license payments to Ablynx.

The two targets were the subject of programmes as part of the research agreement between the parties, entered into in 2005 and extended by mutual agreement last year. Novartis will now assume responsibility for the continued progress of both programmes and Ablynx will be eligible to receive development based milestone payments and royalties on sales following commercialisation of the products.

Dr Edwin Moses, CEO and Chairman of Ablynx, commented: "We are excited to see these two complex programmes progressing towards the clinic in Novartis' hands and pleased that the commercial licenses have been executed. The targets are ones where conventional antibody approaches have had limited success. This is further validation of the unique nature of Ablynx's Nanobody platform, where functional Nanobodies have been successfully generated against GPCRs and ion channels. Earlier this year, we announced that we have selected a new GPCR targeting development candidate, ALX-0651, an anti-CXCR4 Nanobody which is being developed by Ablynx."

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...